Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 23209029)

1.

Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.

Matthay KK.

Clin Cancer Res. 2013 Jan 15;19(2):311-3. doi: 10.1158/1078-0432.CCR-12-3313. Epub 2012 Dec 3.

2.

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.

Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson AD, Boddy AV.

Clin Cancer Res. 2013 Jan 15;19(2):469-79. doi: 10.1158/1078-0432.CCR-12-2225. Epub 2012 Oct 19.

3.

Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group.

Veal GJ, Cole M, Errington J, Pearson AD, Foot AB, Whyman G, Boddy AV; UKCCSG Pharmacology Working Group.

Br J Cancer. 2007 Feb 12;96(3):424-31. Epub 2007 Jan 16.

4.

Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma.

Veal G, Rowbotham S, Boddy A.

Therapie. 2007 Mar-Apr;62(2):91-3. Epub 2007 Jun 21.

PMID:
17582307
5.

Differentiating agents in pediatric malignancies: retinoids in neuroblastoma.

Reynolds CP.

Curr Oncol Rep. 2000 Nov;2(6):511-8. Review.

PMID:
11122886
6.

The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo.

Ponthan F, Borgström P, Hassan M, Wassberg E, Redfern CP, Kogner P.

Med Pediatr Oncol. 2001 Jan;36(1):127-31.

PMID:
11464864
7.

Practical implications for the administration of 13-cis retinoic acid in pediatric oncology.

Bauters TG, Laureys G, Van de Velde V, Benoit Y, Robays H.

Int J Clin Pharm. 2011 Aug;33(4):597-8. doi: 10.1007/s11096-011-9519-9. Review.

PMID:
21544558
8.

Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation.

Khan AA, Villablanca JG, Reynolds CP, Avramis VI.

Cancer Chemother Pharmacol. 1996;39(1-2):34-41.

PMID:
8995497
9.

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP.

N Engl J Med. 1999 Oct 14;341(16):1165-73.

10.

Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.

Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP.

J Clin Oncol. 1995 Apr;13(4):894-901.

PMID:
7707116
11.

Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.

Norris RE, Minturn JE, Brodeur GM, Maris JM, Adamson PC.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1469-75. doi: 10.1007/s00280-011-1623-y. Epub 2011 Apr 12.

12.
13.

About the benefits of immunotherapy for high-risk neuroblastoma.

Moreno L, Barone G, Park JR, Pearson AD.

J Clin Oncol. 2013 Feb 10;31(5):649-50. doi: 10.1200/JCO.2012.47.4080. Epub 2013 Jan 7. No abstract available.

14.
15.

Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.

Weisman RA, Christen R, Los G, Jones V, Kerber C, Seagren S, Glassmeyer S, Orloff LA, Wong W, Kirmani S, Howell S.

Otolaryngol Head Neck Surg. 1998 May;118(5):597-602.

PMID:
9591856
16.

13-cis retinoic acid and isomerisation in paediatric oncology--is changing shape the key to success?

Armstrong JL, Redfern CP, Veal GJ.

Biochem Pharmacol. 2005 May 1;69(9):1299-306. Review.

PMID:
15826600
17.

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK.

J Natl Cancer Inst. 2006 Apr 5;98(7):441-50.

18.

Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells.

Veal GJ, Errington J, Redfern CP, Pearson AD, Boddy AV.

Biochem Pharmacol. 2002 Jan 15;63(2):207-15.

PMID:
11841795
19.

Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma.

Marabelle A, Sapin V, Rousseau R, Periquet B, Demeocq F, Kanold J.

Pediatr Blood Cancer. 2009 Feb;52(2):280-3. doi: 10.1002/pbc.21768.

PMID:
18839433
20.

Hypercalcemia: a dose-limiting toxicity associated with 13-cis-retinoic acid.

Villablanca JG, Khan AA, Avramis VI, Reynolds CP.

Am J Pediatr Hematol Oncol. 1993 Nov;15(4):410-5.

PMID:
8214363
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk